Targeting the central nervous system with herpes simplex virus/sleeping beauty hybrid amplicon vectors

Current Gene Therapy

Volumn 11, Issue 5, 2011, Pages 332-340

  de Silva, Suresh ^a,b   Bowers, William J ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Central nervous system; Gene transfer; HSV 1; Integration; Sleeping beauty

Indexed keywords

BETA GALACTOSIDASE; HERPER SIMPLEX VIRUS VECTOR; HIGH MOBILITY GROUP B1 PROTEIN; SLEEPING BEAUTY HYBRID VECTOR; UNCLASSIFIED DRUG; VIRUS VECTOR;

AMPLICON; ARTICLE; CELL POPULATION; CENTRAL NERVOUS SYSTEM DISEASE; DEGENERATIVE DISEASE; DNA TRANSPOSITION; GENE EXPRESSION; GENE TARGETING; GENE TRANSFER; GENETIC TRANSDUCTION; IMMUNOGENICITY; MOUSE; NEURAL STEM CELL; NONHUMAN; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

HERPES; HUMAN HERPESVIRUS 1;

EID: 80053553032     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/156652311797415845     Document Type: Article

References (64)

1. Simonelli F, Maguire AM, Testa F, et al. Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther 2010; 18: 643-50.
2. Bowers WJ, de Silva S, Federoff HJ. Gene Therapy for Neurological Diseases. In: Templeton NS, editor. Gene and Cell Therapy: Therapeutic Mechanisms and Strategies. 3rd ed. Boca Raton: CRC Press; 2009. p. 833-68.
3. Somia N, Verma IM. Gene therapy: trials and tribulations. Nat Rev Genet 2000; 1: 91-9.
4. Geller AI, Breakefield XO. A defective HSV-1 vector expressesEscherichia coli beta-galactosidase in cultured peripheral neurons. Science 1988; 241: 1667-9.
5. Suzuki M, Kasai K, Saeki Y. Plasmid DNA sequences present inconventional herpes simplex virus amplicon vectors cause rapid transgene silencing by forming inactive chromatin. J Virol 2006;80: 3293-300.
6. Grieger JC, Samulski RJ. Packaging capacity of adeno-associatedvirus serotypes: impact of larger genomes on infectivity and postentry steps. J Virol 2005; 79: 9933-44.
7. Kumar M, Keller B, Makalou N, Sutton RE. Systematic determination of the packaging limit of lentiviral vectors. Hum Gene Ther 2001; 12: 1893-905.
8. Hartung T. Thoughts on limitations of animal models. Parkinsonism Relat Disord 2008; 14 Suppl 2: S81-S3.
9. Gao G, Vandenberghe LH, Wilson JM. New recombinant serotypesof AAV vectors. Curr Gene Ther 2005; 5: 285-97.
10. Su X, Kells AP, Huang EJ, et al. Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys. Hum Gene Ther 2009; 20:1627-40.
11. Herzog CD, Brown L, Gammon D, et al. Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease. Neurosurgery 2009; 64:602-12; discussion 12-3.
12. Kreutzberg GW. Microglia, the first line of defence in brain pathologies. Arzneimittelforschung 1995; 45: 357-60.
13. Wood MJ, Byrnes AP, Pfaff DW, Rabkin SD, Charlton HM. Inflammatory effects of gene transfer into the CNS with defectiveHSV-1 vectors. Gene Ther 1994; 1: 283-91.
14. Spaete RR, Frenkel N. The herpes simplex virus amplicon: a new eucaryotic defective-virus cloning-amplifying vector. Cell 1982;30: 295-304.
15. Olschowka JA, Bowers WJ, Hurley SD, Mastrangelo MA, Federoff HJ. Helper-free HSV-1 amplicons elicit a markedly less robustinnate immune response in the CNS. Mol Ther 2003; 7: 218-27.
16. Burton EA, Fink DJ, Glorioso JC. Gene delivery using herpessimplex virus vectors. DNA Cell Biol 2002; 21: 915-36.
17. Agudo M, Trejo JL, Lim F, et al. Highly efficient and specific gene transfer to Purkinje cells in vivo using a herpes simplex virus Iamplicon. Hum Gene Ther 2002; 13: 665-74.
18. Hadaczek P, Kohutnicka M, Krauze MT, et al. Convection enhanced delivery of adeno-associated virus type 2 (AAV2) into the striatum and transport of AAV2 within monkey brain. Hum Gene Ther 2006; 17: 291-302.
19. Michou AI, Santoro L, Christ M, Julliard V, Pavirani A, Mehtali M. Adenovirus-mediated gene transfer: influence of transgene, mouse strain and type of immune response on persistence of transgene expression. Gene Ther 1997; 4: 473-82.
20. Suzuki M, Chiocca EA, Saeki Y. Early STAT1 activation after systemic delivery of HSV amplicon vectors suppresses transcription of the vector-encoded transgene. Mol Ther 2007; 15:2017-26.
21. Santos K, Simon DA, Conway E, et al. Spatial and temporal expression of herpes simplex virus type 1 amplicon-encoded genes: implications for their use as immunization vectors. Hum Gene Ther 2007; 18: 93-105.
22. Nakai H, Iwaki Y, Kay MA, Couto LB. Isolation of recombinant adeno-associated virus vector-cellular DNA junctions from mouseliver. J Virol 1999; 73: 5438-47.
23. Hadaczek P, Eberling JL, Pivirotto P, Bringas J, Forsayeth J, Bankiewicz KS. Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC. Mol Ther 2010; 18: 1458-61.
24. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348: 255-6.
25. Wang X, Kong L, Zhang GR, Sun M, Geller AI. Apreproenkephalin-neurofilament chimeric promoter in a helpervirus-free herpes simplex virus vector enhances long-term expression in the rat striatum. Neurobiol Dis 2004; 16: 596-603.
26. Gomez-Sebastian S, Gimenez-Cassina A, Diaz-Nido J, Lim F, Wade-Martins R. Infectious delivery and expression of a 135 kbhuman FRDA genomic DNA locus complements Friedreich'sataxia deficiency in human cells. Mol Ther 2007; 15: 248-54.
27. Senior SL, Wade-Martins R. Herpes simplex virus type 1 ampliconvectors for the infectious delivery and expression of genomic DNAloci. Curr Opin Mol Ther 2005; 7: 337-45.
28. Sun M, Kong L, Wang X, et al. Coexpression of tyrosinehydroxylase, GTP cyclohydrolase I, aromatic amino aciddecarboxylase, and vesicular monoamine transporter 2 from ahelper virus-free herpes simplex virus type 1 vector supports highlevel,long-term biochemical and behavioral correction of a ratmodel of Parkinson's disease. Hum Gene Ther 2004; 15: 1177-96.
29. Gao Q, Sun M, Wang X, Zhang GR, Geller AI. Long-terminducible expression in striatal neurons from helper virus-freeHSV-1 vectors that contain the tetracycline-inducible promotersystem. Brain Res 2006; 1083: 1-13.
30. Spaete RR, Frenkel N. The herpes simplex virus amplicon:analyses of cis-acting replication functions. Proc Natl Acad Sci U SA 1985; 82: 694-8.
31. Saeki Y, Breakefield XO, Chiocca EA. Improved HSV-1 amplicon packaging system using ICP27-deleted, oversized HSV-1 BACDNA. Methods Mol Med 2003; 76: 51-60.
32. Vlazny DA, Frenkel N. Replication of herpes simplex virus DNA: localization of replication recognition signals within defective virus genomes. Proc Natl Acad Sci U S A 1981; 78: 742-6.
33. Oehmig A, Fraefel C, Breakefield XO. Update on herpesvirus amplicon vectors. Mol Ther 2004; 10: 630-43.
34. Johnston KM, Jacoby D, Pechan PA, et al. HSV/AAV hybrid amplicon vectors extend transgene expression in human gliomacells. Hum Gene Ther 1997; 8: 359-70.
35. Glauser DL, Ackermann M, Saydam O, Fraefel C. Chimeric herpessimplex virus/adeno-associated virus amplicon vectors. Curr Gene Ther 2006; 6: 315-24.
36. Costantini LC, Jacoby DR, Wang S, Fraefel C, Breakefield XO, Isacson O. Gene transfer to the nigrostriatal system by hybridherpes simplex virus/adeno-associated virus amplicon vectors. Hum Gene Ther 1999; 10: 2481-94.
37. Fraefel C, Jacoby DR, Lage C, et al. Gene transfer into hepatocytes mediated by helper virus-free HSV/AAV hybrid vectors. Mol Med 1997; 3: 813-25.
38. Heilbronn R, Burkle A, Stephan S, zur Hausen H. The adeno-associated virus rep gene suppresses herpes simplex virus-induced DNA amplification. J Virol 1990; 64: 3012-8.
39. Bowers WJ, Mastrangelo MA, Howard DF, Southerland HA, Maguire-Zeiss KA, Federoff HJ. Neuronal precursor-restricte dtransduction via in utero CNS gene delivery of a novel bipartiteHSV amplicon/transposase hybrid vector. Mol Ther 2006; 13: 580-8.
40. Ivics Z, Hackett PB, Plasterk RH, Izsvak Z. Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell 1997; 91: 501-10.
41. Yant SR, Ehrhardt A, Mikkelsen JG, Meuse L, Pham T, Kay MA.Transposition from a gutless adeno-transposon vector stabilizes transgene expression in vivo. Nat Biotechnol 2002; 20: 999-1005.
42. Luo G, Ivics Z, Izsvak Z, Bradley A. Chromosomal transposition of a Tc1/mariner-like element in mouse embryonic stem cells. Proc Natl Acad Sci U S A 1998; 95: 10769-73.
43. Izsvak Z, Ivics Z, Plasterk RH. Sleeping Beauty, a wide host-range transposon vector for genetic transformation in vertebrates. J Mol Biol 2000; 302: 93-102.
44. Karsi A, Moav B, Hackett P, Liu Z. Effects of insert size on transposition efficiency of the sleeping beauty transposon in mousecells. Mar Biotechnol (NY) 2001; 3: 241-5.
45. Geurts AM, Yang Y, Clark KJ, et al. Gene transfer into genomes of human cells by the sleeping beauty transposon system. Mol Ther 2003; 8: 108-17.
46. Zayed H, Izsvak Z, Walisko O, Ivics Z. Development of hyperactive sleeping beauty transposon vectors by mutational analysis. Mol Ther 2004; 9: 292-304.
47. de Silva S, Mastrangelo MA, Lotta LT, Jr., Burris CA, Federoff HJ, Bowers WJ. Extending the transposable payload limit of SleepingBeauty (SB) using the Herpes Simplex Virus (HSV)/SB ampliconvector platform. Gene Ther 2010; 17: 424-31.
48. Bowers WJ, Howard DF, Brooks AI, Halterman MW, Federoff HJ. Expression of vhs and VP16 during HSV-1 helper virus-free amplicon packaging enhances titers. Gene Ther 2001; 8: 111-20.
49. Zayed H, Izsvak Z, Khare D, Heinemann U, Ivics Z. The DNA bending protein HMGB1 is a cellular cofactor of Sleeping Beauty transposition. Nucleic Acids Res 2003; 31: 2313-22.
50. de Silva S, Lotta LT, Burris CA, Bowers WJ. Virion-Associated Cofactor High-Mobility Group DNA-Binding Protein-1 Facilitates Transposition from the Herpes Simplex Virus/Sleeping Beauty Amplicon Vector Platform. Hum Gene Ther 2010; 21: 1615-22.
51. Moldt B, Miskey C, Staunstrup NH, et al. Comparative Genomic Integration Profiling of Sleeping Beauty Transposons Mobilized With High Efficacy From Integrase-defective Lentiviral Vectors in Primary Human Cells. Mol Ther 2011.
52. Yant SR, Wu X, Huang Y, Garrison B, Burgess SM, Kay MA. High-resolution genome-wide mapping of transposon integration in mammals. Mol Cell Biol 2005; 25: 2085-94.
53. Bushman F, Lewinski M, Ciuffi A, et al. Genome-wide analysis of retroviral DNA integration. Nat Rev Microbiol 2005; 3: 848-58.
54. de Silva S, Mastrangelo MA, Lotta LT, et al. Herpes Simplex Virus/Sleeping Beauty Vector-Based Embryonic Gene Transfer Using the HSB5 Mutant: Loss of Apparent Transposition Hyperactivity In Vivo. Hum Gene Ther 2010; 21: 1603-13.
55. Staunstrup NH, Moldt B, Mates L, et al. Hybrid lentivirustransposonvectors with a random integration profile in human cells. Mol Ther 2009; 17: 1205-14.
56. Vink CA, Gaspar HB, Gabriel R, et al. Sleeping beauty transposition from nonintegrating lentivirus. Mol Ther 2009; 17:1197-204.
57. Ivics Z, Katzer A, Stuwe EE, Fiedler D, Knespel S, Izsvak Z. Targeted Sleeping Beauty transposition in human cells. Mol Ther 2007; 15: 1137-44.
58. Peterson EB, Mastrangelo MA, Federoff HJ, Bowers WJ. Neuronal specificity of HSV/sleeping beauty amplicon transduction in uterois driven primarily by tropism and cell type composition. Mol Ther 2007; 15: 1848-55.
59. Wegner M, Stolt CC. From stem cells to neurons and glia: aSoxist's view of neural development. Trends Neurosci 2005; 28:583-8.
60. Caplan AL, Wilson JM. The ethical challenges of in utero genetherapy. Nat Genet 2000; 24: 107.
61. Coutelle C, Rodeck C. On the scientific and ethical issues of fetalsomatic gene therapy. Gene Ther 2002; 9: 670-3.
62. Punzo C, Cepko CL. Ultrasound-guided in utero injections allow studies of the development and function of the eye. Dev Dyn 2008;237: 1034-42.
63. Winchester B, Vellodi A, Young E. The molecular basis of lysosomal storage diseases and their treatment. Biochem Soc Trans 2000; 28: 150-4.
64. Paul CA, Boegle AK, Maue RA. Before the loss: neuronald ysfunction in Niemann-Pick Type C disease. Biochim BiophysActa 2004; 1685: 63-76.